Seelos Therapeutics (SEEL)
(Delayed Data from NSDQ)
$1.75 USD
-0.16 (-8.16%)
Updated May 20, 2024 04:00 PM ET
After-Market: $1.73 -0.02 (-0.86%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Seelos Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 16 | 79 | 16 | 10 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 7 | 5 | 2 | 1 |
Total Current Assets | 5 | 23 | 83 | 17 | 11 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 5 | 23 | 84 | 17 | 11 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 14 | 12 | 1 | 2 | 0 |
Accounts Payable | 16 | 4 | 2 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 7 | 4 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6 | 2 | 2 | 1 | 8 |
Total Current Liabilities | 39 | 25 | 8 | 7 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 8 | 18 | 7 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 39 | 33 | 26 | 15 | 11 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 219 | 204 | 198 | 78 | 56 |
Retained Earnings | -253 | -215 | -141 | -75 | -56 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -34 | -11 | 57 | 3 | 0 |
Total Liabilities & Shareholder's Equity | 5 | 23 | 84 | 17 | 11 |
Total Common Equity | -34 | -11 | 57 | 3 | 0 |
Shares Outstanding | 1.20 | 0.40 | 0.40 | 0.20 | 0.10 |
Book Value Per Share | -27.93 | -26.53 | 143.30 | 12.85 | -0.10 |
Fiscal Year End for Seelos Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 4 | 3 | 6 | 14 |
Receivables | 1 | 0 | 0 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 3 | 6 | 9 |
Total Current Assets | 4 | 5 | 6 | 12 | 24 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 4 | 5 | 6 | 12 | 24 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 13 | 14 | 16 | 12 | 12 |
Accounts Payable | 15 | 16 | 9 | 6 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 3 | 6 | 6 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 6 | 4 | 32 | 16 |
Total Current Liabilities | 37 | 39 | 35 | 56 | 39 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 1 | 3 | 5 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 37 | 39 | 37 | 59 | 44 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 222 | 219 | 217 | 210 | 207 |
Retained Earnings | -255 | -253 | -247 | -258 | -228 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -33 | -34 | -30 | -47 | -21 |
Total Liabilities & Shareholder's Equity | 4 | 5 | 6 | 12 | 24 |
Total Common Equity | -33 | -34 | -30 | -47 | -21 |
Shares Outstanding | 2.00 | 1.20 | 0.60 | 0.50 | 0.50 |
Book Value Per Share | -16.55 | -27.93 | -50.68 | -94.36 | -41.32 |